What is Inflectra and what is it used for?
Inflectra’s active substance is called infliximab which is a type of protein of human and mouse origin.
Inflectra belongs to a group of medicines called “TNF blockers” and it is used in adults for the following inflammatory diseases:
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis (Bechterew’s disease)
Inflectra is also used in adults and children 6 years of age and older for:
- Crohn’s disease
- Ulcerative colitis
Inflectra works by blocking the action of a protein called “tumour necrosis factor alpha” (TNFα). This protein is involved in the inflammatory processes of the body and blocking it can reduce inflammation in the body.
Inflectra is a Prescription Only Medicine and is given by a doctor or nurse in a hospital or clinic as an infusion over a few hours.
The European Medicines Agency (EMA) is an agency of the European Union (EU). The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on Inflectra.
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) since Brexit. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Inflectra please follow these links:
PP-IFA-GBR-0528 / October 2021